Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides compositions of recombinant antibodies that can bind to all the epitopes on allergens recognized by specific human antibody isotypes, notably IgE, IgG4, and IgA. These antibody compositions are used as precise tools to identify which parts of allergens cause allergic reactions, enabling the design of modified, hypoallergenic versions of allergens—called hypoallergenic molecules. These modified allergens maintain the ability to induce protective immune responses, but with greatly reduced potential to trigger allergic reactions, thereby improving the safety and effectiveness of allergy immunotherapy (SIT).

Use CasesContent extracted from patent full text and abstract with AI.

• Development of safer and more effective allergy immunotherapies (SIT) using hypoallergenic molecules.
• Design of diagnostic tools to map epitopes on allergens recognized by different antibody types in allergic patients.
• Production of reference antibody compositions for research or quality control in allergen testing and SIT development.
• Structural analysis of allergen-antibody complexes to understand allergenic mechanisms and improve allergen modification strategies.
• Screening and engineering of allergens in food, environment, pharmaceutical, and cosmetic industries to reduce allergenic potential.

BenefitsContent extracted from patent full text and abstract with AI.

• Allows the rational design of hypoallergenic molecules with reduced ability to bind IgE, minimizing the risk of allergic reactions during therapy.
• Improves the safety, efficacy, and patient compliance of specific immunotherapy (SIT) for allergies.
• Maintains important immunogenic properties (IgG4/IgA epitopes), ensuring long-lasting protective immunity.
• Provides a systematic and precise method to identify all clinically relevant antibody binding sites on allergens.
• Facilitates the development of better diagnostic, therapeutic, and research tools targeting allergies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a composition comprising recombinant antibodies capable of binding to epitopes recognized by antibodies of a specific isotype, in particular, human IgE, IgG4 and/or IgA antibodies, a method of obtaining such a composition and the use of individual antibodies of such a composition as tools for the design of hypoallergenic molecules for specific immunotherapy, as well as a method for generating such hypoallergenic molecules.